Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Briacell Therapeutics Corp T.BCT

Alternate Symbol(s):  BCTX | BCTXW

Healthcare Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted... see more

Recent & Breaking News (TSX:BCT)

BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS(TM) First in Human Study

GlobeNewswire May 28, 2024

BriaCell to report positive cancer research at medical convention

Jonathon Brown May 24, 2024

BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

GlobeNewswire May 24, 2024

BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

GlobeNewswire May 17, 2024

BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering

GlobeNewswire May 15, 2024

BriaCell Announces Oral and Poster Presentations at ASCO 2024

GlobeNewswire April 24, 2024

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+(TM) and Bria-PROS+(TM) Clinical Candidates for Breast and Prostate Cancer

GlobeNewswire April 10, 2024

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

GlobeNewswire April 9, 2024

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

GlobeNewswire March 7, 2024

BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

GlobeNewswire March 6, 2024

BriaCell Provides Update on Alleged Illegal Trading of Public Securities

GlobeNewswire February 27, 2024

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

GlobeNewswire February 7, 2024

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

GlobeNewswire February 6, 2024

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

GlobeNewswire January 30, 2024

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer

GlobeNewswire January 4, 2024

BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

GlobeNewswire December 28, 2023

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

GlobeNewswire December 20, 2023

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

GlobeNewswire December 6, 2023

BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit

GlobeNewswire December 6, 2023

BriaCell Records New Responder with Remarkable Improvement of "Eye-Bulging" Metastatic Tumor

GlobeNewswire November 30, 2023